Cargando…

Anti-Tumor Efficacy of Anti-PD-1/PD-L1 Antibodies in Combination With Other Anticancer Drugs in Solid Tumors: A Systematic Review and Meta-Analysis

BACKGROUND: The clinical efficacy of immune checkpoint inhibitors (CPIs) has been proven; however, it is also known that their efficacy as monotherapy is limited, with a response rate of 20% or less in solid tumors. The combination of CPIs and anticancer agents has been actively attempted in solid t...

Descripción completa

Detalles Bibliográficos
Autores principales: Inoue, Takashi, Narukawa, Mamoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679352/
https://www.ncbi.nlm.nih.gov/pubmed/36748438
http://dx.doi.org/10.1177/10732748221140694